Mavacamten plus supervised exercise for people with obstructive hypertrophic cardiomyopathy
Official title: MavaEnEx-HOCM: Mavacamten Enables Exercise Training in Patients With Hypertrophic Obstructive CardioMyopathy. A Pilot Study
Run by Technical University of Munich · NCT07077005 · Data updated 2026-11-12
This trial tests whether supervised moderate endurance and resistance training is safe and improves fitness for adults with obstructive hypertrophic cardiomyopathy who have been on stable mavacamten treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 24 (estimated) |
| Sponsor | Technical University of Munich Academic / other |
| Locations | 1 site (Munich, Bavaria) |
| Status | Recruiting |
| Started | November 1, 2025 |
| Main results expected | October 31, 2026 |
| Study ends | January 31, 2027 |
| Registry record updated | December 26, 2025 |
| Trial ID | NCT07077005 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with obstructive hypertrophic cardiomyopathy, NYHA class I–II, left ventricular ejection fraction ≥50%, peak LVOT gradient ≤50 mmHg, and at least 12 weeks of unchanged mavacamten therapy are ideal candidates.
✕Probably not a fit
Patients with recent syncope or sustained ventricular tachycardia, significant valve disease, prior septal reduction or ICD implantation, uncontrolled or unanticoagulated atrial fibrillation, a high sudden cardiac death risk score, or those who cannot attend the training site are unlikely to benefit from the supervised exercise intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with hypertrophic obstructive cardiomyopathy who have been on a stable mavacamten dose for at least 12 weeks, have NYHA class I–II, LVEF ≥50% and a peak LVOT gradient ≤50 mmHg undergo either 6 weeks of supervised moderate endurance and resistance training (three times per week) or usual care. Allocation to supervised training versus usual care is determined by travel time to the training site (within 1 hour → training; >1 hour → usual care) at a single center in Munich. Baseline and 6-week follow-up include medical exam, resting and stress echocardiography, blood cardiac biomarkers, a quality-of-life questionnaire (Kansas City Cardiomyopathy Questionnaire) and cardiopulmonary exercise testing to measure peak VO2. Continuous symptom-triggered ECG monitoring with smart watches is provided and the primary outcome is safety, with secondary outcomes including exercise capacity, echocardiographic measures, biomarkers and quality of life.
Why it matters
Potential benefit: If successful, this could show that supervised moderate exercise is safe for selected patients on mavacamten and can improve fitness and quality of life.
How similar studies have gone: Previous supervised exercise programs in carefully selected HCM patients have shown safety and improvements in fitness, but combining structured training specifically while on mavacamten is a novel approach with limited prior data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years of age * Diagnosis of hypertrophic obstructive cardiomyopathy * ≥12 weeks of unchanged dosage of mavacamten * Peak left ventricular outflow tract gradient ≤ 50 mmHg at rest and during stress echocardiography * Left ventricular ejection fraction ≥50% at study inclusion * New York Heart Association classes I-II Exclusion Criteria: * Syncope or sustained ventricular tachycardia within 6 months prior to study inclusion * Corrected QT-interval (Fridericia-formula) ≥ 500 ms * Paroxysmal or intermittent atrial fibrillation (AF) on screening electrocardiogram * Persistent or permanent AF without anticoagulation for ≥4 weeks * Previous transcoronary ablation of septal hypertrophy or surgical myectomy * Ventricular tachycardia, significant ST-elevation or depression upon baseline cardiopulmonary exercise testing * ≥ grade II valve insufficiencies or stenoses during resting echocardiography * Prior implantable cardioverter defibrillator-implantation * Sudden Cardiac Death Risk Score ≥4%
Where it's running
-
Technical University Munich
Munich, Bavaria, Germany Recruiting
Study contacts
- Study coordinator: Simon Wernhart, MD
- Email: simon.wernhart@mri.tum.de
- Phone: 00498941406774
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Registry for hereditary cardiovascular diseases in Brazil
This study is trying to create a registry of Brazilian patients with hereditary heart diseases to see how common certain genetic changes are in people with these conditions.
-
Identifying cardiac amyloidosis in older adults with lumbar spinal stenosis
This study is trying to find out if older adults who have had surgery for lumbar spinal stenosis also have a heart condition called transthyretin cardiac amyloidosis by looking at their spinal tissue and using advanced technology.
-
Comparing hybrid and catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy
This study is testing whether a new hybrid ablation method works better than traditional catheter ablation for controlling heart rhythm in patients with hypertrophic cardiomyopathy and ongoing atrial fibrillation.
-
Observational study on hypertrophic cardiomyopathy in Chinese patients
This study is trying to understand hypertrophic cardiomyopathy in Chinese patients by collecting health information and samples to see how genetics and other factors play a role in the condition and its risks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.